Home
Query results
Results for
PHF21A
Expand for information on PHF21A
PHF21A
Description
PHD finger protein 21A
Aliases
BHC80, BM-006, IDDBCS, NEDMS
Gene Identifiers
mRNA Identifiers
RefSeq (mRNA)
NM_001101802.3; NM_001352025.3; NM_001352026.3; NM_001352027.3; NM_001352028.1; NM_001352029.1; NM_001352030.3; NM_001352031.3; NM_001352032.3; NM_016621.5; XM_005252965.4; XM_011520157.2; XM_011520158.2; XM_011520160.3; XM_011520161.2; XM_011520162.3; XM_011520164.2; XM_011520165.2; XM_011520166.3; XM_011520167.2; XM_011520168.2; XM_011520174.2; XM_011520175.2; XM_011520179.3; XM_017017885.2; XM_017017886.1; XM_017017887.2; XM_017017888.1; XM_017017889.1; XM_017017890.1; XM_017017891.1; XM_017017892.1; XM_017017893.1; XM_017017894.1; XM_017017895.1; XM_017017896.1; XM_017017897.1; XM_017017898.2; XM_017017899.1; XM_017017900.1; XM_017017901.1; XM_017017902.1; XM_017017905.1; XM_017017906.2; XM_017017907.1; XM_017017908.1; XM_024448574.1; XM_024448575.1; XM_024448576.1; XM_024448577.1; XM_024448578.1
Protein Identifiers
RefSeq (protein)
NP_001095272.1; NP_001338954.1; NP_001338955.1; NP_001338956.1; NP_001338957.1; NP_001338958.1; NP_001338959.1; NP_001338960.1; NP_001338961.1; NP_057705.3; XP_005253022.1; XP_011518459.1; XP_011518460.1; XP_011518462.1; XP_011518463.1; XP_011518464.1; XP_011518466.1; XP_011518467.1; XP_011518468.1; XP_011518469.1; XP_011518470.1; XP_011518476.1; XP_011518477.1; XP_011518481.1; XP_016873374.1; XP_016873375.1; XP_016873376.1; XP_016873377.1; XP_016873378.1; XP_016873379.1; XP_016873380.1; XP_016873381.1; XP_016873382.1; XP_016873383.1; XP_016873384.1; XP_016873385.1; XP_016873386.1; XP_016873387.1; XP_016873388.1; XP_016873389.1; XP_016873390.1; XP_016873391.1; XP_016873394.1; XP_016873395.1; XP_016873396.1; XP_016873397.1; XP_024304342.1; XP_024304343.1; XP_024304344.1; XP_024304345.1; XP_024304346.1
Uniprot ID
Ensembl protein ID
Protein Architecture
SMART
Disease Mapping
Druggability
- Candidate cancer driver, TIME driver
- Damaged in 83/7921 TCGA samples
- Damaged in 20/1291 cell lines
- Fewer loss of function mutations
- Equal damaging SNVs/indels
- Fewer structural variants